New drug shows promise in keeping throat cancer at bay
NCT ID NCT04227509
Summary
This study tested whether adding pembrolizumab (an immunotherapy drug) after standard chemoradiation could help prevent cancer from returning in patients with locally advanced nasopharyngeal carcinoma (a type of throat cancer). The trial involved 53 patients who received up to one year of pembrolizumab treatment following their initial therapy. Researchers measured whether patients remained cancer-free for three years after starting treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Internal Medicine, Seoul National University Hospital
Seoul, 110-744, South Korea
Conditions
Explore the condition pages connected to this study.